GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » United Therapeutics Corp (NAS:UTHR) » Definitions » Cyclically Adjusted Revenue per Share

United Therapeutics (United Therapeutics) Cyclically Adjusted Revenue per Share : $41.50 (As of Dec. 2023)


View and export this data going back to 1999. Start your Free Trial

What is United Therapeutics Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

United Therapeutics's adjusted revenue per share for the three months ended in Dec. 2023 was $12.294. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $41.50 for the trailing ten years ended in Dec. 2023.

During the past 12 months, United Therapeutics's average Cyclically Adjusted Revenue Growth Rate was 8.50% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 11.40% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 11.40% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 16.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of United Therapeutics was 35.70% per year. The lowest was 11.40% per year. And the median was 23.20% per year.

As of today (2024-04-27), United Therapeutics's current stock price is $233.85. United Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was $41.50. United Therapeutics's Cyclically Adjusted PS Ratio of today is 5.63.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of United Therapeutics was 15.95. The lowest was 2.88. And the median was 6.15.


United Therapeutics Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for United Therapeutics's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

United Therapeutics Cyclically Adjusted Revenue per Share Chart

United Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 27.48 30.01 34.23 38.25 41.50

United Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 38.25 39.32 40.25 41.09 41.50

Competitive Comparison of United Therapeutics's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, United Therapeutics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


United Therapeutics's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, United Therapeutics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where United Therapeutics's Cyclically Adjusted PS Ratio falls into.



United Therapeutics Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, United Therapeutics's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=12.294/129.4194*129.4194
=12.294

Current CPI (Dec. 2023) = 129.4194.

United Therapeutics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 5.108 99.695 6.631
201406 6.062 100.560 7.802
201409 6.976 100.428 8.990
201412 6.447 99.070 8.422
201503 7.013 99.621 9.111
201506 6.690 100.684 8.599
201509 7.693 100.392 9.917
201512 8.147 99.792 10.566
201603 7.577 100.470 9.760
201606 8.797 101.688 11.196
201609 8.835 101.861 11.225
201612 9.029 101.863 11.472
201703 8.072 102.862 10.156
201706 9.902 103.349 12.400
201709 10.102 104.136 12.555
201712 10.561 104.011 13.141
201803 8.866 105.290 10.898
201806 10.242 106.317 12.468
201809 9.380 106.507 11.398
201812 8.668 105.998 10.583
201903 8.297 107.251 10.012
201906 8.491 108.070 10.168
201909 9.125 108.329 10.901
201912 7.103 108.420 8.479
202003 8.079 108.902 9.601
202006 8.153 108.767 9.701
202009 8.522 109.815 10.043
202012 8.515 109.897 10.028
202103 8.170 111.754 9.461
202106 9.440 114.631 10.658
202109 9.342 115.734 10.447
202112 8.668 117.630 9.537
202203 9.683 121.301 10.331
202206 9.707 125.017 10.049
202209 10.595 125.227 10.950
202212 9.949 125.222 10.283
202303 10.220 127.348 10.386
202306 12.051 128.729 12.116
202309 12.262 129.860 12.220
202312 12.294 129.419 12.294

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


United Therapeutics  (NAS:UTHR) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

United Therapeutics's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=233.85/41.5
=5.63

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of United Therapeutics was 15.95. The lowest was 2.88. And the median was 6.15.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


United Therapeutics Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of United Therapeutics's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


United Therapeutics (United Therapeutics) Business Description

Industry
Traded in Other Exchanges
Address
1040 Spring Street, Silver Spring, MD, USA, 20910
United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.
Executives
Paul A Mahon officer: EVP & General Counsel
Nilda Mesa director C/O UNITED THERAPEUTICS CORPORATION, 1040 SPRING STREET, SILVER SPRING MD 20910
Christopher Causey director
Martine A Rothblatt director, officer: Chief Executive Officer
Louis W Sullivan director
Judy D. Olian director 2000 AVENUE OF THE STARS 12TH FL, LOS ANGELES CA 90067
Michael Benkowitz officer: President and COO C/O UNITED THERAPEUTICS CORP, 1040 SPRING STREET, SILVER SPRING MD 20910
Christopher Patusky director
Raymond Dwek director
Linda Maxwell director 1040 SPRING STREET, SILVER SPRING NC 27709
Tommy G Thompson director 7711 CARONDELET, ST. LOUIS MO 63105
Katherine J Klein director STEINBERG HALL-DIETRICH HALL, 3620 LOCUST WALK, PHILADELPHIA PA 19104
Richard Giltner director C/O UNITED THERAPEUTICS CORPORTION, 1735 CONNECTICUT AVE. NW, WASHINGTON DC 20009
Roger Jeffs director, officer: President and COO
David Zaccardelli officer: EVP & Chief Operating Officer 300 TRI STATE INTERNATIONAL, SUITE 272, LINCOLNSHIRE IL 60069